Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Immunopharmacol Immunotoxicol ; 45(3): 295-303, 2023 Jun.
Article in English | MEDLINE | ID: mdl-36314857

ABSTRACT

BACKGROUND: Sepsis-associated acute kidney injury (AKI) is highlighted by high incidence of mortality and morbidity. Scutellarin is a flavone extracted from certain medicinal plants with anti-inflammatory and anti-oxidative properties. This research study was done to investigate the beneficial effect of scutellarin on lipopolysaccharide (LPS) murine model of AKI. MATERIALS AND METHODS: Five groups of mice were used including control (without LPS injection), LPS group (LPS injection, 10 mg/kg), and LPS + Scutellarin25, 50, and/or 100 groups (receiving scutellarin orally at different doses of 25, 50, or 100 mg/kg before LPS injection). RESULTS: Scutellarin pretreatment effectively lowered kidney function markers (BUN, creatinine, and cystatin C), improved superoxide dismutase (SOD) besides enhancement of level, and/or gene expression for nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and heme oxygenase 1 (HO-1) and also reduced oxidative stress factors including reactive oxygen species (ROS) and malondialdehyde (MDA). In addition, scutellarin reduced tissue level and/or gene expression of inflammatory markers comprising toll-like receptor 4 (TLR4), nuclear factor-kappaB (NF-κB), and tumor necrosis factor α (TNF-α) and properly raised anti-inflammatory factor IL-10. Moreover, scutellarin enhanced mitochondrial membrane potential (MMP) and attenuated histopathological changes in renal tissue subsequent to LPS challenge. Beneficial effects of scutellarin was associated with improvement of gene expression regarding peroxisome proliferator-activated receptor gamma (PPARγ) and its coactivator PGC-1α as specific markers of mitochondrial biogenesis. CONCLUSION: These results indicate that scutellarin could protect against LPS-provoked AKI through restraining inflammation and oxidative stress and maintenance of mitochondrial health and biogenesis which is partly mediated through its regulation of Nrf2/PPAR-γ/PGC-1α/NF-kB/TLR4.


Subject(s)
Acute Kidney Injury , Lipopolysaccharides , Mice , Animals , Lipopolysaccharides/toxicity , Toll-Like Receptor 4/metabolism , NF-E2-Related Factor 2/metabolism , Oxidative Stress , NF-kappa B/metabolism , Acute Kidney Injury/chemically induced , Acute Kidney Injury/drug therapy , Acute Kidney Injury/metabolism , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Mitochondria/metabolism
2.
Pharm Biol ; 55(1): 958-965, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28166686

ABSTRACT

CONTEXT: Anxiety and depression are common in Alzheimer's disease (AD). Despite some evidence, it is difficult to confirm Lavandula officinalis Chaix ex Vill (Lamiaceae) as an anxiolytic and antidepressant drug. OBJECTIVE: The effects of L. officinalis extract were studied in scopolamine-induced memory impairment, anxiety and depression-like behaviour. MATERIALS AND METHODS: Male NMRI rats were divided into control, scopolamine alone-treated group received scopolamine (0.1 mg/kg) intraperitoneally (i.p.), daily and 30 min prior to performing behavioural testing on test day, for 12 continuous days and extract pretreated groups received aerial parts hydro alcoholic extract (i.p.) (100, 200 and 400 mg/kg), 30 min before each scopolamine injection. Memory impairment was assessed by Y-maze task, while, elevated plus maze and forced swimming test were used to measure anxiolytic and antidepressive-like activity. RESULTS: Spontaneous alternation percentage in Y maze is reduced by scopolamine (36.42 ± 2.60) (p ≤ 0.001), whereas lavender (200 and 400 mg/kg) enhanced it (83.12 ± 5.20 and 95 ± 11.08, respectively) (p ≤ 0.05). Also, lavender pretreatment in 200 and 400 mg/kg enhanced time spent on the open arms (15.4 ± 3.37 and 32.1 ± 3.46, respectively) (p ≤ 0.001). On the contrary, while immobility time was enhanced by scopolamine (296 ± 4.70), 100, 200 and 400 mg/kg lavender reduced it (193.88 ± 22.42, 73.3 ± 8.25 and 35.2 ± 4.22, respectively) in a dose-dependent manner (p ≤ 0.001). DISCUSSION AND CONCLUSION: Lavender extracts improved scopolamine-induced memory impairment and also reduced anxiety and depression-like behaviour in a dose-dependent manner.


Subject(s)
Anti-Anxiety Agents/pharmacology , Antidepressive Agents/pharmacology , Anxiety/prevention & control , Behavior, Animal/drug effects , Depression/prevention & control , Lavandula/chemistry , Memory Disorders/prevention & control , Plant Components, Aerial/chemistry , Plant Extracts/pharmacology , Scopolamine , Animals , Anti-Anxiety Agents/isolation & purification , Antidepressive Agents/isolation & purification , Anxiety/chemically induced , Anxiety/psychology , Chromatography, High Pressure Liquid , Depression/chemically induced , Depression/psychology , Disease Models, Animal , Dose-Response Relationship, Drug , Ethanol/chemistry , Male , Maze Learning/drug effects , Memory/drug effects , Memory Disorders/chemically induced , Memory Disorders/psychology , Motor Activity/drug effects , Phenols/isolation & purification , Phenols/pharmacology , Phytotherapy , Plant Extracts/isolation & purification , Plants, Medicinal , Rats , Solvents/chemistry , Swimming , Time Factors
3.
Mini Rev Med Chem ; 17(8): 721-726, 2017.
Article in English | MEDLINE | ID: mdl-27903228

ABSTRACT

BACKGROUND: Thiazolidinediones (TZDs) and sulfonamides are important and highly consumption class of antidiabetic drugs having insulin sensitizing and stimulating properties in patients with type 2 diabetes, respectively. OBJECTIVE: In this paper, some novel benzothiazole derivatives of TZD-sulfonamides were synthesized (I-IV) and evaluated for anti-hyperglycemic and anti-hyperlipidemic activities in the STZ-induced diabetic rat model. RESULTS: Results indicated that all new conjugated compounds showed significant hypoglycemic activities compared to control animals that were better for I and IV than others. Moreover, these new compounds displayed high efficiency for lowering lipid profiles as compared to control and standard (Pioglitazone) groups that was significant and higher for I than others. CONCLUSION: It is concluded that these new conjugated TZD-sulfonamide-benzothiazoles (I-IV) can indicate useful results for hypoglycemic and hypolipidemic activities compared to control and standard groups, respectively with different mechanism that is closer to TZDs' analogs.


Subject(s)
Benzothiazoles/therapeutic use , Diabetes Mellitus, Experimental/drug therapy , Hypoglycemic Agents/therapeutic use , Sulfonamides/therapeutic use , Thiazolidinediones/therapeutic use , Animals , Benzothiazoles/chemistry , Diabetes Mellitus, Experimental/chemically induced , Hypoglycemic Agents/chemical synthesis , Hypoglycemic Agents/chemistry , Molecular Structure , Rats , Streptozocin , Sulfonamides/chemical synthesis , Sulfonamides/chemistry , Thiazolidinediones/chemical synthesis , Thiazolidinediones/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...